Terms: = Uterine cancer AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2 AND Staging
3 results:
1. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
[TBL] [Abstract] [Full Text] [Related]
2. Malignant changes in adenomyosis in patients with endometrioid adenocarcinoma.
Kucera E; Hejda V; Dankovcik R; Valha P; Dudas M; Feyereisl J
Eur J Gynaecol Oncol; 2011; 32(2):182-4. PubMed ID: 21614909
[TBL] [Abstract] [Full Text] [Related]
3. Neoadjuvant chemotherapy followed by radical hysterectomy and postoperative adjuvant chemotherapy in the treatment of carcinoma of the cervix uteri: long-term follow-up of a pilot study.
Sananes C; Giaroli A; Soderini A; Guardado N; Snaidas L; Bermudez A; Ferreira M; di Paola G; Sardi J
Eur J Gynaecol Oncol; 1998; 19(4):368-73. PubMed ID: 9744728
[TBL] [Abstract] [Full Text] [Related]
